MARKSANS
MARKSANS PHARMA LIMITED
Each stock's 10,000-path forecast, rendered as light.
MARKSANS PHARMA LIMITED (MARKSANS) Stock Analysis & Case Study
Is MARKSANS a good buy? The data-driven verdict.
MARKSANS PHARMA LIMITED (MARKSANS) trades at ₹274,on the numbers it mixed signals, a Downstox Snapshot Score of 46/100.
On the numbers, MARKSANS PHARMA LIMITED (MARKSANS) mixed signals, a Downstox Snapshot Score of 46/100, weighing premium at 29.8× earnings, ROE of 15.2%, a 52% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
MARKSANS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How MARKSANS ranks against the 2,373 companies in our screener
- MARKSANS's market cap of 12,410 Cr ranks in the 78th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MARKSANS's book value of ₹67 ranks in the 40th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MARKSANS's promoter holding of 43.9% ranks in the 21st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MARKSANS's 3-year profit (PAT) growth of 16.0% ranks in the 50th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MARKSANS's 3-year revenue growth of 17.0% ranks in the 67th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MARKSANS's debt-to-equity ratio of 0.11x is lower than 75% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is MARKSANS overvalued? MARKSANS P/E vs peers
MARKSANS trades at 29.8× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
MARKSANS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of MARKSANS history (18%/yr drift, 47%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| MARKSANS 2027 | ₹155 | ₹281 | ₹509 | +3% |
| MARKSANS 2028 | ₹126 | ₹288 | ₹661 | +5% |
| MARKSANS 2029 | ₹106 | ₹296 | ₹829 | +8% |
| MARKSANS 2030 | ₹89 | ₹304 | ₹1,033 | +11% |
| MARKSANS 2031 | ₹82 | ₹312 | ₹1,192 | +14% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability MARKSANS goes up, or doubles?
The bull case for MARKSANS
- MARKSANS's return on equity of 15.2% ranks in the 72nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MARKSANS's return on capital employed of 18.8% ranks in the 77th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹829.
The bear case & risks
- MARKSANS's P/E of 29.8x is lower than 46% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- High historical volatility (47%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹106.
MARKSANS volatility & expected range, how bumpy is the ride?
Over the last 9.8 years MARKSANS compounded at 18%/year with annualized volatility of 47%. That volatility implies a 1-year 80% range of ₹155-₹509, the honest backbone behind any single price target.
MARKSANS price forecast, the full 60-month probability fan
MARKSANS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds MARKSANS hits common targets within the simulated horizon?
Full multi-horizon detail on the MARKSANS price target & forecast page.
MARKSANS Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. MARKSANS scores 6/8, mixed financial health.
MARKSANS MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy MARKSANS with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.73% | 2.8× |
| Zerodha | 35.70% | 2.8× |
| Groww | 35.87% | 2.8× |
| Dhan | 35.70% | 2.8× |
| Kotak Neo | 35.71% | 2.8× |
| Paytm Money | 36.02% | 2.8× |
| PocketfulCHEAPEST | 35.63% | 2.8× |
| Anand Rathi | 35.70% | 2.8× |
| Bajaj Broking | 37.00% | 2.7× |
| Share India | 35.83% | 2.8× |
Compare every broker on the MARKSANS MTF page.
About MARKSANS PHARMA LIMITED: sector, index & market-cap context
MARKSANS PHARMA LIMITED (MARKSANS) is a small-cap NSE-listed company, with a market capitalisation of ₹12,410 Cr. See more stocks on our screener.
How the MARKSANS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of MARKSANS PHARMA LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
MARKSANS analysis, FAQs
Is MARKSANS PHARMA LIMITED (MARKSANS) a good buy?
On the numbers, MARKSANS PHARMA LIMITED (MARKSANS) mixed signals, a Downstox Snapshot Score of 46/100, weighing premium at 29.8× earnings, ROE of 15.2%, a 52% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is MARKSANS overvalued or undervalued?
MARKSANS trades at 29.8× earnings, premium versus the ~22× long-run Nifty average.
What is the MARKSANS share price target for 2031?
MARKSANS's probability-weighted 2031 median target is ₹312, with an 80% range of ₹82-₹1,192 (10,000-path Monte-Carlo).
What is the probability MARKSANS doubles in 5 years?
The modelled probability of MARKSANS reaching ₹548 (2×) within 5 years is 30%.
What is the bull case for MARKSANS?
MARKSANS's return on equity of 15.2% ranks in the 72nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. MARKSANS's return on capital employed of 18.8% ranks in the 77th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in MARKSANS?
MARKSANS's P/E of 29.8x is lower than 46% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. High historical volatility (47%/yr) means a wide, bumpy range of outcomes, size positions accordingly.